Advertisement

Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET

  • Jochen Hammes
  • Isabel Leuwer
  • Gérard N. Bischof
  • Alexander Drzezga
  • Thilo van Eimeren
Original Article

Abstract

Purpose

Cerebral glucose metabolism measured with [18F]-FDG PET is a well established marker of neuronal dysfunction in neurodegeneration. The tau-protein tracer [18F]-AV-1451 PET is currently under evaluation and shows promising results. Here, we assess the feasibility of early perfusion imaging with AV-1451 as a substite for FDG PET in assessing neuronal injury.

Methods

Twenty patients with suspected neurodegeneration underwent FDG and early phase AV-1451 PET imaging. Ten one-minute timeframes were acquired after application of 200 MBq AV-1451. FDG images were acquired on a different date according to clinical protocol. Early AV-1451 timeframes were coregistered to individual FDG-scans and spatially normalized. Voxel-wise intermodal correlations were calculated on within-subject level for every possible time window. The window with highest pooled correlation was considered optimal. Z-transformed deviation maps (ZMs) were created from both FDG and early AV-1451 images, comparing against FDG images of healthy controls.

Results

Regional patterns and extent of perfusion deficits were highly comparable to metabolic deficits. Best results were observed in a time window from 60 to 360 s (r = 0.86). Correlation strength ranged from r = 0.96 (subcortical gray matter) to 0.83 (frontal lobe) in regional analysis. ZMs of early AV-1451 and FDG images were highly similar.

Conclusion

Perfusion imaging with AV-1451 is a valid biomarker for assessment of neuronal dysfunction in neurodegenerative diseases. Radiation exposure and complexity of the diagnostic workup could be reduced significantly by routine acquisition of early AV-1451 images, sparing additional FDG PET.

Keywords

Av-1451 Tau-imaging Cerebral perfusion Cerebral FDG metabolism Neurodegeneration 

Notes

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

IL, GNB and JH report no potential conflicts of interest. AD received consulting and speaker honoraria and research support from Siemens Healthcare, AVID Radiopharmaceuticals, Lilly, Piramal, and GE Healthcare. TvE received lecture fees from Lilly Germany, and research funding from the German Research Foundation (DFG), the Leibniz Association and the EU-joint program for neurodegenerative disease research (JPND).

References

  1. 1.
    Bischof GN, Jessen F, Fliessbach K, et al. Impact of tau and amyloid burden on glucose metabolism in Alzheimer’s disease. Ann Clin Transl Neurol. 2016;3:934–9.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dronse J, Fliessbach K, Bischof GN, et al. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease. J Alzheimers Dis. 2016:1–7.Google Scholar
  3. 3.
    Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Spina S, Schonhaut DR, Boeve BF, et al. Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations. Neurology. 2017;88:758–66.CrossRefPubMedGoogle Scholar
  5. 5.
    Dani M, Brooks DJ, Edison P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2016;43:1139–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Hammes J, Bischof GN, Giehl K, et al. Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Mov Disord. 2017;32:170–1.CrossRefPubMedGoogle Scholar
  7. 7.
    Cho H, Choi JY, Hwang MS, et al. Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord. 2017;32:134–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Whitwell JL, Lowe VJ, Tosakulwong N, et al. [18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2017;32:124–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Smith R, Schain M, Nilsson C, et al. Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord. 2017;32:108–14.CrossRefPubMedGoogle Scholar
  10. 10.
    Betthauser T, Lao PJ, Murali D, et al. In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317. J Nucl Med. 2017;58:996–1002.CrossRefPubMedGoogle Scholar
  11. 11.
    Xia C-F, Arteaga J, Chen G, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 2013;9:666–76.CrossRefPubMedGoogle Scholar
  12. 12.
    Walji AM, Hostetler ED, Selnick H, et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59:4778–89.CrossRefPubMedGoogle Scholar
  13. 13.
    van Eimeren T, Bischof GN, Drzezga AE. Is tau imaging more than just ‘upside-down’ FDG imaging? J Nucl Med; Epub ahead of print 10 May 2017.  https://doi.org/10.2967/jnumed.117.190082.
  14. 14.
    Ng KP, Pascoal TA, Mathotaarachchi S, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F–THK5351 uptake in the human brain. Alzheimers Res Ther; 9. Epub ahead of print 31 March 2017.  https://doi.org/10.1186/s13195-017-0253-y.
  15. 15.
    Saint-Aubert L, Lemoine L, Chiotis K, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12:19.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Teipel S, Drzezga A, Grothe MJ, et al. Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol. 2015;14:1037–53.CrossRefPubMedGoogle Scholar
  17. 17.
    Heiss WD, Herholz K, Pawlik G, et al. Positron emission tomography as a quantitative imaging method for demonstrating regional brain metabolism. Digitale Bilddiagn. 1984;4:37–45.PubMedGoogle Scholar
  18. 18.
    Phillips AA, Chan FH, Zheng MMZ, et al. Neurovascular coupling in humans: Physiology, methodological advances and clinical implications. J Cereb Blood Flow Metab. 2016;36:647–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Mielke R, Pietrzyk U, Jacobs A, et al. HMPAO SPET and FDG PET in Alzheimer’s disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med. 1994;21:1052–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Tiepolt S, Hesse S, Patt M, et al. Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2016;43:1700–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Rostomian AH, Madison C, Rabinovici GD, et al. Early 11C-PIB frames and 18F-FDG PET measures are comparable: A study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52:173–9.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Meyer PT, Hellwig S, Amtage F, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393–400.CrossRefPubMedGoogle Scholar
  23. 23.
    Lin K-J, Hsiao I-T, Hsu J-L, et al. Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2016;43:1304–14.CrossRefPubMedGoogle Scholar
  24. 24.
    Hsiao I-T, Huang C-C, Hsieh C-J, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613–20.CrossRefPubMedGoogle Scholar
  25. 25.
    Jin S, Oh M, Oh SJ, et al. Additional value of early-phase 18F-FP-CIT PET image for differential diagnosis of atypical parkinsonism. Clin Nucl Med. 2017;42:e80–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Verfaillie SCJ, Adriaanse SM, Binnewijzend MAA, et al. Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin? Eur Radiol. 2015;25:3050–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Rodriguez-Vieitez E, Leuzy A, Chiotis K, et al. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer’s disease. J Cereb Blood Flow Metab. 2016; 0271678X16645593 Google Scholar
  28. 28.
    Evans AC, Collins DL, Mills SR, et al. 3D statistical neuroanatomical models from 305 MRI volumes. In: Nuclear Science Symposium and Medical Imaging Conference, 1993., 1993 I.E. Conference Record. 1993, pp. 1813–1817 vol.3.Google Scholar
  29. 29.
    Fisher RA. Frequency distribution of the values of the correlation coefficient in samples from an indefinitely large population. Biometrika. 1915;10:507–21.Google Scholar
  30. 30.
    Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47.CrossRefPubMedGoogle Scholar
  31. 31.
    Makris N, Goldstein JM, Kennedy D, et al. Decreased volume of left and total anterior insular lobule in schizophrenia. Schizophr Res. 2006;83:155–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage. 2002;15:273–89.CrossRefPubMedGoogle Scholar
  33. 33.
    Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of Fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–48.PubMedGoogle Scholar
  34. 34.
    Vollmar S, Čížek J, Sué M, et al. VINCI-volume imaging in neurological research, co-registration and ROIs included. In: Kremer K, Macho V, editors. Forschung und wissenschaftliches Rechnen 2003. Göttingen: GWDG; 2004. p. 115–31.Google Scholar
  35. 35.
    Wong CO, Thie J, Gaskill M, et al. A statistical investigation of normal regional intra-subject heterogeneity of brain metabolism and perfusion by F-18 FDG and O-15 H2O PET imaging. BMC Nucl Med. 2006;6:4.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Schonhaut DR, Ossenkoppele R, Bejanin A, et al. Tau-pet patterns overlap and exceed hypometabolism in Alzheimer’s disease. Alzheimers Dement. 2016;12:545–P547.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Multimodal Neuroimaging Group, Department of Nuclear MedicineUniversity Hospital CologneCologneGermany
  2. 2.INM-3, Research Center JülichJülichGermany
  3. 3.German Center for Neurodegeneration (DZNE)BerlinGermany

Personalised recommendations